Developing guidelines for biotechnology drug use: Experience with antithrombin III

D. R. Romac, P. Poole, John T Owings, K. Mahackian, G. Foulke, R. S. Tharratt, Timothy E Albertson

Research output: Contribution to journalArticle

Abstract

Development of institutional guidelines for use of high-cost biotechnology drugs, such as antithrombin III, is a valuable tool in formulary management. This article describes the process by which the University of California Davis Medical Center used an ad hoc committee to the P and T Committee to develop guidelines for antithrombin III use. Performing an objective analysis of available literature to address the appropriate role of a biotechnology agent is necessary to develop consensus guidelines. Approval of use guidelines by the P and T Committee provides the necessary structure for optimal use of biotechnology agents, such as antithrombin III.

Original languageEnglish (US)
Pages (from-to)520-531
Number of pages12
JournalFormulary
Volume30
Issue number9
StatePublished - 1995

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Developing guidelines for biotechnology drug use: Experience with antithrombin III'. Together they form a unique fingerprint.

  • Cite this

    Romac, D. R., Poole, P., Owings, J. T., Mahackian, K., Foulke, G., Tharratt, R. S., & Albertson, T. E. (1995). Developing guidelines for biotechnology drug use: Experience with antithrombin III. Formulary, 30(9), 520-531.